Sold as Aristocort, Kenacort. Every FDA application for this active ingredient: 4 branded and 4 generic.
As of Nov 15, 2026, FDA lists 8 applications for Triamcinolone Diacetate (sold as Aristocort, Kenacort), first approved Mar 12, 1959, with 0 new uses approved and 0 published complete response letters.
| Mar 12, 1959 | AristocortNDA 11685 · New active ingredient | Fosun Pharma | 12 | Discontinued |
| Sep 2, 1959 | AristocortNDA 11960 · New dosage form | Astellas | 3 | Discontinued |
| Mar 21, 1961 | KenacortNDA 12515 · New formulation or manufacturer | Delcor Asset Corp | 8 | Discontinued |
| Sep 5, 1961 | AristocortNDA 12802 · New formulation or manufacturer | Fosun Pharma | 17 | Discontinued |
| Jan 24, 1977 | Triamcinolone DiacetateANDA 84072 | Watson Labs | 16 | Discontinued |
| — | Triamcinolone DiacetateANDA 85122 | Epic Pharma LLC | 0 | Discontinued |
| — | Triamcinolone DiacetateANDA 85529 | Watson Labs | 0 | Discontinued |
| — | Triamcinolone DiacetateANDA 86394 | Epic Pharma LLC | 0 | Discontinued |
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Drugs@FDA
Astellas